Retinitis Pigmentosa (Retinitis) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) – Pipeline Review, H2 2017’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)

The report reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Retinitis Pigmentosa (Retinitis) therapeutics and enlists all their major and minor projects

The report assesses Retinitis Pigmentosa (Retinitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

Acucela Inc

Allergan Plc

Amarantus Bioscience Holdings Inc

Amgen Inc

Applied Genetic Technologies Corp

Astellas Pharma Inc

Caladrius Biosciences Inc

Dompe Farmaceutici SpA

Eyevensys SAS

GenSight Biologics SA

Grupo Ferrer Internacional SA

ID Pharma Co Ltd

InFlectis BioScience

Ionis Pharmaceuticals Inc

M's Science Corp

MimeTech Srl

Mimetogen Pharmaceuticals Inc

Nanovector srl

Novartis AG

Novelion Therapeutics Inc

ProQR Therapeutics NV

Recursion Pharmaceuticals Inc

ReNeuron Group Plc

SanBio Inc

Sanofi

Spark Therapeutics Inc

Sun Pharma Advanced Research Company Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Retinitis Pigmentosa (Retinitis) Overview 8

Retinitis Pigmentosa (Retinitis) Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Retinitis Pigmentosa (Retinitis) Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Retinitis Pigmentosa (Retinitis) Companies Involved in Therapeutics Development 28

2-BBB Medicines BV 28

Acucela Inc 28

Allergan Plc 28

Amarantus Bioscience Holdings Inc 29

Amgen Inc 29

Applied Genetic Technologies Corp 30

Astellas Pharma Inc 30

Caladrius Biosciences Inc 31

Dompe Farmaceutici SpA 31

Eyevensys SAS 32

GenSight Biologics SA 32

Grupo Ferrer Internacional SA 33

ID Pharma Co Ltd 33

InFlectis BioScience 33

Ionis Pharmaceuticals Inc 34

M's Science Corp 34

MimeTech Srl 35

Mimetogen Pharmaceuticals Inc 35

Nanovector srl 35

Novartis AG 36

Novelion Therapeutics Inc 36

ProQR Therapeutics NV 37

Recursion Pharmaceuticals Inc 37

ReNeuron Group Plc 38

SanBio Inc 38

Sanofi 39

Spark Therapeutics Inc 39

Sun Pharma Advanced Research Company Ltd 40

Retinitis Pigmentosa (Retinitis) Drug Profiles 41

A-004 Drug Profile 41

AGTC-501 Drug Profile 43

AMRS-001 Drug Profile 45

Antibodies to Antagonize IL-6 for Retinitis Drug Profile 54

Antisense Oligonucleotides to Activate Usherin for Retinitis Pigmentosa Drug Profile 55

AP-1 Drug Profile 56

cenegermin Drug Profile 57

CPK-850 Drug Profile 60

cutamesine Drug Profile 61

EYS-611 Drug Profile 63

FAB-111 Drug Profile 64

Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa Drug Profile 65

Gene Therapy for Glaucoma and Retinitis Pigmentosa Drug Profile 66

Gene Therapy for Ocular Diseases Drug Profile 67

Gene Therapy for Retinitis Pigmentosa Drug Profile 68

Gene Therapy for Retinitis Pigmentosa Drug Profile 69

Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa Drug Profile 70

Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa Drug Profile 71

Gene Therapy to Activate MERTK for Retinitis Pigmentosa Drug Profile 72

Gene Therapy to Activate mVChR1 for Retinits Pigmentosa Drug Profile 73

Gene Therapy to Activate RdCVF for Retinitis Pigmentosa Drug Profile 74

Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa Drug Profile 75

Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa Drug Profile 76

GS-030 Drug Profile 77

HORAPDE-6B Drug Profile 80

HORARLBP-1 Drug Profile 81

HORARPE-65 Drug Profile 82

IFB-088 Drug Profile 83

IONISRHO-2.5Rx Drug Profile 84

KIRA-6 Drug Profile 85

KUS-121 Drug Profile 86

KUS-187 Drug Profile 87

LPDF-003 Drug Profile 88

MT-8 Drug Profile 89

myriocin Drug Profile 90

N-acetyl cysteine amide Drug Profile 91

NPI-001 Drug Profile 92

NT-501 Drug Profile 93

OCU-100 Drug Profile 96

QRX-411 Drug Profile 97

QRX-421 Drug Profile 98

ReN-003 Drug Profile 99

RST-001 Drug Profile 103

SAR-421869 Drug Profile 105

SB-623 Drug Profile 107

Small Molecule for Retinitis Pigmentosa Drug Profile 112

Small Molecules 1 for Retinitis Pigmentosa Drug Profile 113

Small Molecules 2 for Retinitis Pigmentosa Drug Profile 114

Small Molecules 3 for Retinitis Pigmentosa Drug Profile 115

Small Molecules 4 for Retinitis Pigmentosa Drug Profile 116

Small Molecules for Retinitis Pigmentosa Drug Profile 117

Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa Drug Profile 118

Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis Drug Profile 119

STC-1 Drug Profile 120

Stem Cell Therapy for AMD and Retinitis Pigmentosa Drug Profile 121

Stem Cell Therapy for Ophthalmic Disorders Drug Profile 123

Stem Cell Therapy for Retinitis Pigmentosa Drug Profile 125

Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration Drug Profile 126

Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa Drug Profile 128

voretigene neparvovec Drug Profile 129

zuretinol acetate Drug Profile 135

Retinitis Pigmentosa (Retinitis) Dormant Projects 141

Retinitis Pigmentosa (Retinitis) Discontinued Products 143

Retinitis Pigmentosa (Retinitis) Product Development Milestones 144

Featured News & Press Releases 144

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

List of Tables

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by 2-BBB Medicines BV, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Acucela Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Allergan Plc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Amarantus Bioscience Holdings Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Amgen Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Applied Genetic Technologies Corp, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Astellas Pharma Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Caladrius Biosciences Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Dompe Farmaceutici SpA, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Eyevensys SAS, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by GenSight Biologics SA, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Grupo Ferrer Internacional SA, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by ID Pharma Co Ltd, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by InFlectis BioScience, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by M's Science Corp, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by MimeTech Srl, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Mimetogen Pharmaceuticals Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Nanovector srl, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Novartis AG, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Novelion Therapeutics Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by ProQR Therapeutics NV, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Recursion Pharmaceuticals Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by ReNeuron Group Plc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by SanBio Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Sanofi, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Spark Therapeutics Inc, H2 2017

Retinitis Pigmentosa (Retinitis) Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Retinitis Pigmentosa (Retinitis) Dormant Projects, H2 2017

Retinitis Pigmentosa (Retinitis) Dormant Projects, H2 2017 (Contd..1), H2 2017

Retinitis Pigmentosa (Retinitis) Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports